Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy

Research output: Contribution to journalReview articlepeer-review

Standard

Extra-thymically induced T regulatory cell subsets : the optimal target for antigen-specific immunotherapy. / Verhagen, Johan; Wegner, Anja; Wraith, David.

In: Immunology, Vol. 145, No. 2, 06.2015, p. 171-181.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{67c2d7b7e59348de930c189b57800b8c,
title = "Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy",
abstract = "Antigen-specific immunotherapy aims to selectively restore tolerance to innocuous antigens in cases of autoimmune or allergic disease, without the need for general immune suppression. Although the principle of antigen-specific immunotherapy was discovered more than a century ago, its clinical application to date is limited, particularly in the control of autoimmunity. This has resulted mainly from a lack of in-depth understanding of the underlying mechanism. More recently, the differentiation of extra-thymically induced T regulatory (Treg) cell subsets has been shown to be instrumental in peripheral tolerance induction. Two main types of inducible Treg cells, interleukin-10-secreting or Foxp3+, have now been described, each with distinct characteristics and methods of therapeutic induction. It is crucial, therefore, to identify the suitability of either subset in the control of specific immune disorders. This review explores their natural function, the known mechanisms of therapeutic differentiation of either subset as well as their in vivo functionality and discusses new developments that may aid their use in antigen-specific immunotherapy, with a focus on autoimmune disease.",
keywords = "Animals, Antigens, Autoimmune Diseases, Cell Differentiation, Forkhead Transcription Factors, Humans, Hypersensitivity, Immune Tolerance, Immunotherapy, Interleukin-10, T-Lymphocytes, Regulatory, Journal Article, Research Support, Non-U.S. Gov't, Review, antigen specificity, Foxp3, regulatory T cell",
author = "Johan Verhagen and Anja Wegner and David Wraith",
note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",
year = "2015",
month = jun,
doi = "10.1111/imm.12458",
language = "English",
volume = "145",
pages = "171--181",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley",
number = "2",

}

RIS

TY - JOUR

T1 - Extra-thymically induced T regulatory cell subsets

T2 - the optimal target for antigen-specific immunotherapy

AU - Verhagen, Johan

AU - Wegner, Anja

AU - Wraith, David

N1 - © 2015 John Wiley & Sons Ltd.

PY - 2015/6

Y1 - 2015/6

N2 - Antigen-specific immunotherapy aims to selectively restore tolerance to innocuous antigens in cases of autoimmune or allergic disease, without the need for general immune suppression. Although the principle of antigen-specific immunotherapy was discovered more than a century ago, its clinical application to date is limited, particularly in the control of autoimmunity. This has resulted mainly from a lack of in-depth understanding of the underlying mechanism. More recently, the differentiation of extra-thymically induced T regulatory (Treg) cell subsets has been shown to be instrumental in peripheral tolerance induction. Two main types of inducible Treg cells, interleukin-10-secreting or Foxp3+, have now been described, each with distinct characteristics and methods of therapeutic induction. It is crucial, therefore, to identify the suitability of either subset in the control of specific immune disorders. This review explores their natural function, the known mechanisms of therapeutic differentiation of either subset as well as their in vivo functionality and discusses new developments that may aid their use in antigen-specific immunotherapy, with a focus on autoimmune disease.

AB - Antigen-specific immunotherapy aims to selectively restore tolerance to innocuous antigens in cases of autoimmune or allergic disease, without the need for general immune suppression. Although the principle of antigen-specific immunotherapy was discovered more than a century ago, its clinical application to date is limited, particularly in the control of autoimmunity. This has resulted mainly from a lack of in-depth understanding of the underlying mechanism. More recently, the differentiation of extra-thymically induced T regulatory (Treg) cell subsets has been shown to be instrumental in peripheral tolerance induction. Two main types of inducible Treg cells, interleukin-10-secreting or Foxp3+, have now been described, each with distinct characteristics and methods of therapeutic induction. It is crucial, therefore, to identify the suitability of either subset in the control of specific immune disorders. This review explores their natural function, the known mechanisms of therapeutic differentiation of either subset as well as their in vivo functionality and discusses new developments that may aid their use in antigen-specific immunotherapy, with a focus on autoimmune disease.

KW - Animals

KW - Antigens

KW - Autoimmune Diseases

KW - Cell Differentiation

KW - Forkhead Transcription Factors

KW - Humans

KW - Hypersensitivity

KW - Immune Tolerance

KW - Immunotherapy

KW - Interleukin-10

KW - T-Lymphocytes, Regulatory

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

KW - antigen specificity

KW - Foxp3

KW - regulatory T cell

U2 - 10.1111/imm.12458

DO - 10.1111/imm.12458

M3 - Review article

C2 - 25716063

VL - 145

SP - 171

EP - 181

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 2

ER -